Invite only: Chemical, biological, radiological and nuclear (CBRN) medical countermeasures R&D

Upcoming UKRI funding opportunity · Grant. Opens 2026-11-05; closes 2027-01-20. Opportunity page: https://www.ukri.org/opportunity/invite-only-chemical-biological-radiological-and-nuclear-cbrn-medical-countermeasures-rd/

Apply for funding to develop and test novel therapeutics, medical devices, diagnostics and other interventions across any stage of the developmental pathway, from prototype development, through pre-clinical refinement, to early-phase clinical studies (up to phase 2a) for CBRN threats.

Applications must demonstrate how the proposed research will result in improved domestic preparedness for CBRN threats.

There is a funding limit of £4 million per application and requested costs should be appropriate to the project. We will fund 80% of a project’s full economic cost (FEC).

The duration of your project should be up to 30 months.

You must have submitted a mandatory expression of interest (EOI) and be invited to submit a full application.

What we're looking for Scope

Funding is available for pre-clinical and early translational research on the development of medical countermeasures (MCMs) for chemical, biological, radiological and nuclear (CBRN) threats. Your project can start and finish at any stage on the developmental pathway from early prototype development, through pre-clinical refinement and testing, to early-phase clinical studies and trials (up to phase 2a).

Projects must generate evidence which contributes to improving domestic preparedness for CBRN incidents, particularly improving the health system’s preparedness.  Examples include:

- the development of novel vaccines, diagnostics and therapeutics for CBRN threats

- broad-spectrum interventions for CBRN exposure

- symptomatic management approaches to treat CBRN exposure

- medicines repurposing studies, using existing therapies for the treatment of CBRN threats

Priority areas for research are:

- broad spectrum MCMs for threats that focus on treating shared symptomology or…